TY  - JOUR
A1  - Minckwitz, Gunter von
A1  - Harder, Sebastian
A1  - Hövelmann, Sascha
A1  - Jäger, Elke
A1  - Batran, Salah-Eddin al-
A1  - Loibl, Sibylle
A1  - Atmaca, Akin
A1  - Cimpoiasu, Christian
A1  - Neumann, Antje
A1  - Abera, Aklil
A1  - Knuth, Alexander
A1  - Kaufmann, Manfred
A1  - Jäger, Dirk
A1  - Maurer, Alexander B.
A1  - Wels, Winfried
T1  - Correction : phase I clinical study of the recombinant antibody-toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
T2  - Breast cancer research
N2  - Following publication of the data presented by von Minckwitz and colleagues it has been brought to our attention that some patients should be scored differently. Stable disease was seen in three of the eighteen patients instead of two of the eighteen patients: one patient with transitional cell carcinoma treated at 4 µg/kg scFv(FRP5)-ETA per day, and two breast cancer patients treated at 4 and 12.5 µg/kg scFv(FRP5)-ETA per day. Disease progression occured in 9 of the eighteen patients evaluated (see corrected Table 2 overleaf). This does not affect the conclusions of our study. In addition we would like to correct the following errors: patient IDs for patients U01 and U02 in the original Table 2 were interchanged. In addition, patient N03 had a grade 3 elevation of gamma-glutamyl transferase, and not grade 2 (see corrected Table 2 overleaf).
Y1  - 2006
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/1036
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30-44520
SN  - 1465-5411
SN  - 1465-542X
N1  - © 2006 BioMed Central Ltd
VL  - 8
IS  - 1, Art. 403
SP  - 1
EP  - 2
PB  - BioMed Central
CY  - London
ER  -